Succeeding With The FDA: Answers To Seven Common Questions About IND Submissions
Source: Premier Consulting

Submission of an Investigational New Drug Application (IND) is a milestone in new drug development, marking the transition from bench research to clinical studies in human participants. Successful IND submission requires careful planning and strict compliance with regulatory requirements, which can be especially challenging for first-time applicants. In this article, get answers to seven questions commonly received about developing a timely and well-structured IND submission.
Examples of questions:
- What is the structure of the Common Technical Document?
- What is the purpose and value of a pre-IND meeting?
- Can foreign data be included in the IND?
- What are the requirements for manufacturing in the IND?
- What is the regulatory timeline for U.S. IND submissions?
access the Q&A!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more